BioTuesdays

Roth starts Immune Pharma at buy

Immune Pharmaceuticals

Roth Capital Partners has initiated coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $6 price target. The stock closed at $1.21 on Wednesday.

Immune is developing bertilimumab in combating multiple inflammatory diseases, with the ability for a companion diagnostic to help drive success, writes analyst Joseph Pantginis. The company is also developing a platform technology called NanomAbs, which could represent the next targeted approach to treating cancer, he added.

Bertilimumab is currently in two Phase 2 studies for bullous pemphigoid (BP) and ulcerative colitis (UC). Other planned indications the company intends to pursue are severe asthma, atopic dermatitis and non-alcoholic steatohepatitis.

Mr. Pantginis said his model assigns value only to the two ongoing clinical programs in BP and UC. “For BP, we estimate a product launch in 2020, $250-million peak sales at five years post-launch and 15% probability of success,” he said. “For UC, we estimate a product launch in 2021, $700-million peak sales at five years post-launch and 15% probability of success.”

The NanomAbs platform offers the ability to develop nano-encapsulated cytotoxic agents, which target tumors specifically through antibodies linked to the particles. Mr. Pantginis said this approach is meant to specifically deliver a drug or drugs into tumor cells and it is a new approach to developing antibody-drug conjugates.

The company is currently in the preclinical stages of development of its first NanomAb candidate, trastuzumab-nano-paclitaxel, for breast cancer with first-in-human study initiation anticipated in 2017, he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.